▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / ENTX

ENTX — Entera Bio Ltd.

—
· Health Care · Biotechnology · CIK 1638097 · Israel
Last close
$2.99
Market Cap
$147.38M
52W High
$4.20
52W Low
$1.07
ADV30
5,103,883
Next earnings
—
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 0 -3,539,000 -3,505,000 13,129,000 4,137,000 2,442,000
Dec 2025 0 0 -3,042,000 -3,016,000 15,993,000 7,108,000 2,892,000
Sep 2025 0 0 -3,256,000 -3,200,000 17,407,000 8,574,000 2,173,000
Jun 2025 0 0 -2,668,000 -2,656,000 19,667,000 10,858,000 2,411,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,370,000
Investing CF
$-107,000
Financing CF
$13,710,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.27
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-125,366,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-11,529,000
Pretax Income TTM
$-11,439,000
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-12,476,000
Free Cash Flow
$-4,841,625
Enterprise Value
$143,494,704
Total Cash
$4,137,000
Total Debt
$448,000
Shares Out
49,290,234
Trailing EPS
$-0.26
Book Value
$0.23
ROE
-82.3%
ROA
-45.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 42,000 -11,529,000 -11,439,000 15,993,000 2,892,000 — -7,370,000
Dec 2024 181,000 -9,585,000 -9,541,000 9,390,000 1,310,000 — -6,818,000
Dec 2023 0 -8,891,000 -8,889,000 11,765,000 1,379,000 — -7,310,000
Dec 2022 134,000 -13,017,000 -13,071,000 13,127,000 1,373,000 — -12,499,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.55

Max Pain — expiry 2026-08-21

max pain strike: $2.50 · spot: $2.99 · call oi: 707 · put oi: 1,958
Expected Move to 2026-08-21: ±$0.55 (18.56%) — implied range $2.44 – $3.55 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MOLN MOLECULAR PARTNERS AG $147.42M $3.93 —
CRDL Cardiol Therapeutics Inc. $146.40M $1.27 —
CRBU Caribou Biosciences, Inc. $144.80M $1.46 —
IPHYF Innate Pharma SA $154.94M $1.65 —
ABOS Acumen Pharmaceuticals, Inc. $155.29M $2.15 —

News headlines (Yahoo Finance, 1h cache)

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-31 20:30 · Yahoo
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
2026-07-27 12:30 · Yahoo
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
2026-07-21 14:39 · Yahoo
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
2026-06-22 18:29 · Yahoo
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
2026-06-22 12:30 · Yahoo
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
2026-06-16 12:33 · Yahoo
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
2026-06-15 12:45 · Yahoo
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline
2026-05-28 12:50 · Yahoo
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
2026-05-08 20:05 · Yahoo
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know
2026-04-29 16:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →